Growth factor analysis of low-grade glioma CSF: PDGF and VEGF are not detectable

2003 ◽  
Vol 24 (2) ◽  
pp. 70-73 ◽  
Author(s):  
D. Ribom ◽  
A. Larsson ◽  
K. Pietras ◽  
A. Smits
2017 ◽  
Author(s):  
D Usta ◽  
F Selt ◽  
J Hohloch ◽  
S Pusch ◽  
SM Pfister ◽  
...  

2021 ◽  
Vol 22 (3) ◽  
pp. 184-195
Author(s):  
Lily Deland ◽  
Simon Keane ◽  
Thomas Olsson Bontell ◽  
Helene Sjögren ◽  
Henrik Fagman ◽  
...  

2020 ◽  
Vol 1693 ◽  
pp. 012135
Author(s):  
Dan Xu ◽  
Xidong Zhou ◽  
Xuefen Niu ◽  
Junwei Wang

2021 ◽  
Vol 10 (5) ◽  
pp. 1054
Author(s):  
Sean M. Barber ◽  
Saeed S. Sadrameli ◽  
Jonathan J. Lee ◽  
Jared S. Fridley ◽  
Bin S. Teh ◽  
...  

Chordoma is a low-grade notochordal tumor of the skull base, mobile spine and sacrum which behaves malignantly and confers a poor prognosis despite indolent growth patterns. These tumors often present late in the disease course, tend to encapsulate adjacent neurovascular anatomy, seed resection cavities, recur locally and respond poorly to radiotherapy and conventional chemotherapy, all of which make chordomas challenging to treat. Extent of surgical resection and adequacy of surgical margins are the most important prognostic factors and thus patients with chordoma should be cared for by a highly experienced, multi-disciplinary surgical team in a quaternary center. Ongoing research into the molecular pathophysiology of chordoma has led to the discovery of several pathways that may serve as potential targets for molecular therapy, including a multitude of receptor tyrosine kinases (e.g., platelet-derived growth factor receptor [PDGFR], epidermal growth factor receptor [EGFR]), downstream cascades (e.g., phosphoinositide 3-kinase [PI3K]/protein kinase B [Akt]/mechanistic target of rapamycin [mTOR]), brachyury—a transcription factor expressed ubiquitously in chordoma but not in other tissues—and the fibroblast growth factor [FGF]/mitogen-activated protein kinase kinase [MEK]/extracellular signal-regulated kinase [ERK] pathway. In this review article, the pathophysiology, diagnosis and modern treatment paradigms of chordoma will be discussed with an emphasis on the ongoing research and advances in the field that may lead to improved outcomes for patients with this challenging disease.


2021 ◽  
pp. 179-183
Author(s):  
Ann-Kristin Becker ◽  
Marta Leonora Frank ◽  
Michael Friese ◽  
Joachim Röther

The most malignant type of intrinsic brain tumor is glioblastoma (WHO grade IV). Primary leptomeningeal spread is rare and leads to a variety of differential considerations, as there is no typical clinical or imaging pattern. Here we present a rare and uncommon case of a primary leptomeningeal glioblastoma in combination with a low-grade glioma in a 21-year-old male, initially presenting with only headache and lower back pain. The presented case illustrates the challenging differential considerations and the severe course of leptomeningeal glioblastomas.


Sign in / Sign up

Export Citation Format

Share Document